Premium
PHASE I CLINICAL TRIAL OF CD19‐TARGETED 19‐28Z/4‐1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION
Author(s) -
Batlevi C.L.,
Palomba M.L.,
Park J.,
Mead E.,
Santomasso B.,
Riviere I.,
Wang X.,
Senechal B.,
Furman R.,
Yang J.,
Kane P.,
Hall M.,
Bernal Y.,
Lund N.,
Diamonte C.,
Pineda J.,
Halton E.,
Moskowitz C.,
Younes A.,
Sadelain M.,
Brentjens R.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.124_2629
Subject(s) - medicine , fludarabine , cyclophosphamide , lymphoma , gastroenterology , immunology , oncology , chemotherapy